RT Journal Article
SR Electronic
T1 Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation, France, December 2021 - February 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.24.22272871
DO 10.1101/2022.03.24.22272871
A1 Bal, Antonin
A1 Simon, Bruno
A1 Destras, Gregory
A1 Chalvignac, Richard
A1 Semanas, Quentin
A1 Oblette, Antoine
A1 Queromes, Gregory
A1 Fanget, Remi
A1 Regue, Hadrien
A1 Morfin, Florence
A1 Valette, Martine
A1 Lina, Bruno
A1 Josset, Laurence
YR 2022
UL http://medrxiv.org/content/early/2022/03/27/2022.03.24.22272871.abstract
AB In Dec 2021-Feb 2022, an intense and unprecedented co-circulation of SARS-CoV-2 variants with high genetic diversity raised the question of possible co-infections between variants and how to detect them. Using 11 mixes of Delta:Omicron isolates at different ratios, we evaluated the performance of 4 different sets of primers used for whole-genome sequencing and we developed an unbiased bioinformatics method which can detect all co-infections irrespective of the SARS-CoV-2 lineages involved. Applied on 21,387 samples collected between weeks 49-2021 and 08-2022 from random genomic surveillance in France, we detected 53 co-infections between different lineages. The prevalence of Delta and Omicron (BA.1) co-infections and Omicron lineages BA.1 and BA.2 co-infections were estimated at 0.18% and 0.26%, respectively. Among 6,242 hospitalized patients, the intensive care unit (ICU) admission rates were 1.64%, 4.81% and 15.38% in Omicron, Delta and Delta/Omicron patients, respectively. No BA.1/BA.2 co-infections were reported among ICU admitted patients. Although SARS-CoV-2 co-infections were rare in this study, their proper detection is crucial to evaluate their clinical impact and the risk of the emergence of potential recombinants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSante publique France, the French national public health agency. Caisse nationale d assurance maladie (Cnam), the national health insurance funds. Grant : Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the COVID-19 pandemic in the European Union and European Economic Area (Grant Agreement ECDC/HERA/2021/007 ECDC 12221)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA Number 41).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe GISAID accession numbers of the Delta and Omicron virus isolates used for experimental mixes are EPI_ISL_11171170 and EPI_ISL_11171169, respectively. Sequencing data of the Delta:Omicron mixes were deposited on the SRA database under accession PRJNA817870, and dehosted sequencing data of NPS with co-infections were deposited under accession PRJNA817806.